首藥控股(688197.SH):核心自研產品均處於研發階段,尚未有產品上市貢獻銷售收入
格隆匯3月14日丨首藥控股(688197.SH)公佈股票交易異常波動公吿,公司日常運營情況一切正常,全力推進核心管線的註冊臨牀研究。截至本公吿披露日,核心自研產品SY-707基於註冊臨牀Ⅲ期試驗結果正在進行pre-NDA的溝通交流;第三代ALK抑制劑SY-3505針對二代ALK抑制劑治療失敗的NSCLC關鍵性Ⅱ期試驗正在快速入組過程中,對比克唑替尼一線治療ALK陽性NSCLC患者的關鍵性Ⅲ期臨牀研究已於2023年12月正式啟動;選擇性RET抑制劑SY-5007針對RET陽性NSCLC的關鍵性Ⅱ期試驗已經完成全部受試者入組,註冊Ⅲ期確證性臨牀研究於2023年7月正式啟動,目前均在快速推進過程中。截至本公吿披露日,公司核心自研產品均處於研發階段,尚未有產品上市貢獻銷售收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.